Tirofiban

Drug Profile

Tirofiban

Alternative Names: Aggrastat; L 462; L 700462; MK 0383; MK 383; Tirofiban HCl

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Developer 4P Therapeutics; Cardiome Pharma; Eddingpharm; Medicure
  • Class Antiplatelets; Aromatic amino acids; Ischaemic heart disorder therapies
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Arterial thrombosis; Myocardial infarction; Unstable angina pectoris
  • No development reported Coronary artery restenosis

Most Recent Events

  • 16 Feb 2017 Tirofiban is available for licensing as of 16 Feb 2017. http://cardiome.ca/partners/ (Cardiome Pharma pipeline, February 2017)
  • 14 Oct 2016 Cardiome Pharma re-launches tirofiban for unstable Angina pectoris in Canada
  • 01 Sep 2016 USFDA approves bolus vial as new product format for administration of tirofiban in treatment of acute coronary syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top